Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00909363 · ClinicalTrials.gov registry record · Phase 2
Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT00909363: Clinical Trial Phase 2 study, sponsored by Weill Medical College of Cornell University.
NCT00909363 is a Phase 2 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00909363, a Phase 2 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this project is to describe the pathophysiology of thrombocytopenia and bleeding in patients with Wiskott-Aldrich Syndrome (WAS) and determine the response to thrombopoietic agents in vitro and in vivo.
Primary Outcome
number of WAS patients achieving this increase to \> 50,000/uL without rescue medication in the previous 3 weeks during eltrombopag treatment
Interventions
- DRUG Promacta
- DIAGNOSTIC_TEST blood drawing in patients with WAS
- DIAGNOSTIC_TEST blood drawing in healthy controls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2009-06 |
| Est. Completion | 2017-06-30 |
| Phase | Phase 2 |
Why NCT00909363 stopped before completion
NCT00909363 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 3 interventions - of which Promacta is the first listed.
NCT00909363 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00909363 about?
NCT00909363 is a clinical study titled "Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients". The purpose of this project is to describe the pathophysiology of thrombocytopenia and bleeding in patients with Wiskott-Aldrich Syndrome (WAS) and determine the response to thrombopoietic agents in vitro and in vivo.
What is the current status of trial NCT00909363?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2009-06. Estimated completion is 2017-06-30.
What interventions are being tested in trial NCT00909363?
The interventions under investigation include: Promacta (DRUG), blood drawing in patients with WAS (DIAGNOSTIC_TEST), blood drawing in healthy controls (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT00909363?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00909363's enrollment target sits among peer trials
24 1756th of 2000 higher than 217 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia